Forward
Monday, November 23, 2015  |  Volume 7 / Number 24  |  A Production of the BioProcessing Journal
Career Development
ASCB Annual Meeting 2015
December 12–16, 2015
San Diego, California USA
CMC Strategy Forum
January 2016
January 25, 2016
WCBP 2016
January 26–28, 2016
Washington, DC USA
Phacilitate
Washington 2016
January 25–27, 2016
Washington, DC USA
ASGCT 19th Annual Meeting
May 4–7, 2016
Washington, DC USA
PREP 2016—29th International Symposium on Preparative and Process Chromatography
July 17–20, 2016
Philadelphia,
Pennsylvania USA
Techno-Blast Masthead
A whimsical Thanksgiving feast for the eyes. Original image featured on the cover of the BioProcessing Journal Summer 2011 issue (Vol. 10, No. 1): Confocal fluorescence image of Indian Muntjac deer skin fibroblast cells.

— Image provided by
Michael W. Davidson,
National High Magnetic
Field Laboratory
(www.microscopy.fsu.edu),
The Florida State University, Tallahassee

Email your cell images to the editor today!
Suggested Reading
A Qualitative Risk-Benefit Structure for Developing and Manufacturing Biopharmaceuticals
By Mark F. Witcher, PhD, Integrated Project Services (IPS)
Sponsored Link
Manufacture of product for clinical trials can be expensive. Next to skill- and labor-intensive PD work and the hands-on expertise required for operations, much of the expense comes from using the same purification materials that you will use later for 100s of cycles in full-scale production.

Why not try a fresh and “Lean” approach?

Purolite’s new Praesto AC Protein A resin is specifically designed for MAb capture steps in production for PI and PII – with capacity over 30 mg/mL at 3 minutes residence time, excellent pressure/flow performance, and NaOH CIP stability for up to 20 cycles. Why pay for 200+ cycles when you likely will run less than 20?

And, Praesto AC is available pre-packed in ProcessReady columns – ready-to-use and sized for early stage production runs.

A fresh approach from an established supplier – process excellence and balanced economy.



Contact us to learn more.

+44 1443 229334 | lifesciences@purolite.com | www.purolitelifesciences.com
Products & Services
New Variable Flow Control Valve
BioPure Technology, part of Watson-Marlow Fluid Technology Group (WMFTG), announces its BioValve® variable flow control valve, a precision restriction flow controller and shut-off valve for use in bioprocessing and pharmaceutical manufacturing applications.

BioValve features a profile designed to minimize flow path turbulence. The valve’s thread pitch is calibrated to 2mm per turn, delivering highly controlled flow restriction even with single-handed use.
BioValve® variable flow control valve BioValve control valves are produced from reinforced nylon USP Class VI, and are suitable for sterilization by autoclave and gamma irradiation up to 40 kGy, making them ideal for biopharmaceutical applications. Every BioValve is permanently molded with production lot numbers to ensure full traceability, and the product is available in two different sizes to accommodate a range of tube diameters.

BioPure also offers advanced single-use tube and connector systems. Drawing on considerable single-use expertise, BioPure Technology provides the flexibility of customized fluid path solutions to suit a range of bioprocessing needs. For more information, please visit biopuretech.com.
New Video on ADCC Assays
Sartorius Stedim Biotech (SSB) BioOutsource has posted a new video explaining how to overcome the issues associated with using antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the factors affecting the use of ADCC assays and discusses what to consider when determining comparability and designing biosimilar drugs.
In just five minutes, bioassay development experts describe the challenges of using ADCC assays and explain when to use each type of assay to assess biosimilars. Dr. Thomson lists four key reasons why ADCC activity is the greatest road-block to achieving approval of biosimilars and, with real ADCC assay data, shows what a biosimilar which has poor comparability to the innovator molecule looks like. Dr. Galbraith reveals the science behind ADCC assays and describes with real data how different types of effector cells can dramatically affect biological relevance and sensitivity. This provides scientists with a quick snap-shot as to which ADCC assay format is most relevant for the current stage of their biosimilar’s development.

To access the video, please visit https://youtu.be/Ps2ukqj7dq4.
Career Development
Transmission Raman
Seminar
December 3, 2015
Oxford, United Kingdom
5th Annual Meeting
January 23–27, 2016
San Diego, California USA
7th Monolith Summer School and Symposium
May 27–June 1, 2016
Portorož, Slovenia
BPJ Publishing
Advertising
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Don't finalize your media plans without consulting
our media kit!
Email us to request a copy.
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]